Cargando…

Novel Axl-driven signaling pathway and molecular signature characterize high-grade ovarian cancer patients with poor clinical outcome

High-grade epithelial ovarian cancer (HGEOC) is a clinically diverse and molecularly heterogeneous disease comprising subtypes with distinct biological features and outcomes. The receptor tyrosine kinases, expressed by EOC cells, and their ligands, present in the microenvironment, activate signaling...

Descripción completa

Detalles Bibliográficos
Autores principales: Rea, Katia, Pinciroli, Patrizia, Sensi, Marialuisa, Alciato, Federica, Bisaro, Brigitte, Lozneanu, Ludmila, Raspagliesi, Francesco, Centritto, Floriana, Cabodi, Sara, Defilippi, Paola, Avanzi, Gian Carlo, Canevari, Silvana, Tomassetti, Antonella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741573/
https://www.ncbi.nlm.nih.gov/pubmed/26356564
_version_ 1782414021508464640
author Rea, Katia
Pinciroli, Patrizia
Sensi, Marialuisa
Alciato, Federica
Bisaro, Brigitte
Lozneanu, Ludmila
Raspagliesi, Francesco
Centritto, Floriana
Cabodi, Sara
Defilippi, Paola
Avanzi, Gian Carlo
Canevari, Silvana
Tomassetti, Antonella
author_facet Rea, Katia
Pinciroli, Patrizia
Sensi, Marialuisa
Alciato, Federica
Bisaro, Brigitte
Lozneanu, Ludmila
Raspagliesi, Francesco
Centritto, Floriana
Cabodi, Sara
Defilippi, Paola
Avanzi, Gian Carlo
Canevari, Silvana
Tomassetti, Antonella
author_sort Rea, Katia
collection PubMed
description High-grade epithelial ovarian cancer (HGEOC) is a clinically diverse and molecularly heterogeneous disease comprising subtypes with distinct biological features and outcomes. The receptor tyrosine kinases, expressed by EOC cells, and their ligands, present in the microenvironment, activate signaling pathways, which promote EOC cells dissemination. Herein, we established a molecular link between the presence of Gas6 ligand in the ascites of HGEOCs, the expression and activation of its receptor Axl in ovarian cancer cell lines and biopsies, and the progression of these tumors. We demonstrated that Gas6/Axl signalling converges on the integrin β3 pathway in the presence of the adaptor protein p130Cas, thus inducing tumor cell adhesion to the extracellular matrix and invasion. Accordingly, Axl and p130Cas were significantly co-expressed in HGEOC samples. Clinically, we identified an Axl-associated signature of 62 genes able to portray the HGEOCs with the shortest overall survival. These data biologically characterize a group of HGEOCs and could help guide a more effective therapeutic approach to be taken for these patients.
format Online
Article
Text
id pubmed-4741573
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-47415732016-03-03 Novel Axl-driven signaling pathway and molecular signature characterize high-grade ovarian cancer patients with poor clinical outcome Rea, Katia Pinciroli, Patrizia Sensi, Marialuisa Alciato, Federica Bisaro, Brigitte Lozneanu, Ludmila Raspagliesi, Francesco Centritto, Floriana Cabodi, Sara Defilippi, Paola Avanzi, Gian Carlo Canevari, Silvana Tomassetti, Antonella Oncotarget Research Paper High-grade epithelial ovarian cancer (HGEOC) is a clinically diverse and molecularly heterogeneous disease comprising subtypes with distinct biological features and outcomes. The receptor tyrosine kinases, expressed by EOC cells, and their ligands, present in the microenvironment, activate signaling pathways, which promote EOC cells dissemination. Herein, we established a molecular link between the presence of Gas6 ligand in the ascites of HGEOCs, the expression and activation of its receptor Axl in ovarian cancer cell lines and biopsies, and the progression of these tumors. We demonstrated that Gas6/Axl signalling converges on the integrin β3 pathway in the presence of the adaptor protein p130Cas, thus inducing tumor cell adhesion to the extracellular matrix and invasion. Accordingly, Axl and p130Cas were significantly co-expressed in HGEOC samples. Clinically, we identified an Axl-associated signature of 62 genes able to portray the HGEOCs with the shortest overall survival. These data biologically characterize a group of HGEOCs and could help guide a more effective therapeutic approach to be taken for these patients. Impact Journals LLC 2015-09-04 /pmc/articles/PMC4741573/ /pubmed/26356564 Text en Copyright: © 2015 Rea et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Rea, Katia
Pinciroli, Patrizia
Sensi, Marialuisa
Alciato, Federica
Bisaro, Brigitte
Lozneanu, Ludmila
Raspagliesi, Francesco
Centritto, Floriana
Cabodi, Sara
Defilippi, Paola
Avanzi, Gian Carlo
Canevari, Silvana
Tomassetti, Antonella
Novel Axl-driven signaling pathway and molecular signature characterize high-grade ovarian cancer patients with poor clinical outcome
title Novel Axl-driven signaling pathway and molecular signature characterize high-grade ovarian cancer patients with poor clinical outcome
title_full Novel Axl-driven signaling pathway and molecular signature characterize high-grade ovarian cancer patients with poor clinical outcome
title_fullStr Novel Axl-driven signaling pathway and molecular signature characterize high-grade ovarian cancer patients with poor clinical outcome
title_full_unstemmed Novel Axl-driven signaling pathway and molecular signature characterize high-grade ovarian cancer patients with poor clinical outcome
title_short Novel Axl-driven signaling pathway and molecular signature characterize high-grade ovarian cancer patients with poor clinical outcome
title_sort novel axl-driven signaling pathway and molecular signature characterize high-grade ovarian cancer patients with poor clinical outcome
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741573/
https://www.ncbi.nlm.nih.gov/pubmed/26356564
work_keys_str_mv AT reakatia novelaxldrivensignalingpathwayandmolecularsignaturecharacterizehighgradeovariancancerpatientswithpoorclinicaloutcome
AT pincirolipatrizia novelaxldrivensignalingpathwayandmolecularsignaturecharacterizehighgradeovariancancerpatientswithpoorclinicaloutcome
AT sensimarialuisa novelaxldrivensignalingpathwayandmolecularsignaturecharacterizehighgradeovariancancerpatientswithpoorclinicaloutcome
AT alciatofederica novelaxldrivensignalingpathwayandmolecularsignaturecharacterizehighgradeovariancancerpatientswithpoorclinicaloutcome
AT bisarobrigitte novelaxldrivensignalingpathwayandmolecularsignaturecharacterizehighgradeovariancancerpatientswithpoorclinicaloutcome
AT lozneanuludmila novelaxldrivensignalingpathwayandmolecularsignaturecharacterizehighgradeovariancancerpatientswithpoorclinicaloutcome
AT raspagliesifrancesco novelaxldrivensignalingpathwayandmolecularsignaturecharacterizehighgradeovariancancerpatientswithpoorclinicaloutcome
AT centrittofloriana novelaxldrivensignalingpathwayandmolecularsignaturecharacterizehighgradeovariancancerpatientswithpoorclinicaloutcome
AT cabodisara novelaxldrivensignalingpathwayandmolecularsignaturecharacterizehighgradeovariancancerpatientswithpoorclinicaloutcome
AT defilippipaola novelaxldrivensignalingpathwayandmolecularsignaturecharacterizehighgradeovariancancerpatientswithpoorclinicaloutcome
AT avanzigiancarlo novelaxldrivensignalingpathwayandmolecularsignaturecharacterizehighgradeovariancancerpatientswithpoorclinicaloutcome
AT canevarisilvana novelaxldrivensignalingpathwayandmolecularsignaturecharacterizehighgradeovariancancerpatientswithpoorclinicaloutcome
AT tomassettiantonella novelaxldrivensignalingpathwayandmolecularsignaturecharacterizehighgradeovariancancerpatientswithpoorclinicaloutcome